Metamark Announces Appointment of Dr. Peter Blume-Jensen to its Scientific Advisory Board
6/12/2014 | Press Release
CAMBRIDGE, Massachusetts, June 12, 2014 – Metamark today announced that its Chief Scientific Officer, Peter Blume-Jensen, M.D., Ph.D., will be joining a targeted therapeutics startup, and will continue working for Metamark as a member of the company’s Scientific Advisory Board and as a consultant.
“We wish to sincerely thank Peter for his significant contributions to Metamark, and in particular, the ProMark™ development effort. We are pleased that Peter will remain closely engaged with us as we commercialize ProMark™,” said Metamark CEO Shawn Marcell. “Peter has been, and continues to be, a thought leader in prostate oncology as the standards of care evolve and new prognostic modalities become available.”
ProMark™ is designed to improve the accuracy of prognosis for men diagnosed with prostate cancer, specifically the approximately 85% of prostate cancer patients with biopsy Gleason grades 3+3 or 3+4 for whom standard-of-care medical decision making is currently insufficient. The test measures the amount of specific protein biomarkers obtained by needle biopsy from regions of prostate tissue where the biomarkers are altered during tumor formation. These “regions of interest” are rendered as intact, paraffin-embedded tissue sections. Quantitative measurements of the biomarkers are then determined by means of imaging technology that is
digitized and fully automated. The resulting analysis is thus completely objective and fully reproducible. A large, blinded, clinical-validation study of ProMark™ met its primary endpoint, demonstrating that the test can aid in differentiating between aggressive and indolent disease. The research program supporting ProMark™ has completed four clinical studies altogether, and additional prospective studies are underway. Metamark plans to commercialize ProMark™ in 2014 through the company's CLIA-certified laboratory in Cambridge, Massachusetts. For more information, visit: www.metamarkgenetics.com.
Metamark is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of Healthtronics Laboratory Solutions last year, Metamark has become a leading provider of specialty urological pathology testing services throughout the United States. For more information, please visit the company's website at www.metamarkgenetics.com.
Metamark™ and ProMark™ are trademarks of Metamark.